Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5281056
Max Phase: Preclinical
Molecular Formula: C16H10N4
Molecular Weight: 258.28
Associated Items:
ID: ALA5281056
Max Phase: Preclinical
Molecular Formula: C16H10N4
Molecular Weight: 258.28
Associated Items:
Canonical SMILES: c1ccc2c(c1)[nH]c1cnc3c4ccncc4[nH]c3c12
Standard InChI: InChI=1S/C16H10N4/c1-2-4-11-9(3-1)14-13(19-11)8-18-15-10-5-6-17-7-12(10)20-16(14)15/h1-8,19-20H
Standard InChI Key: RZXWKGHDRQNABH-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 258.28 | Molecular Weight (Monoisotopic): 258.0905 | AlogP: 3.75 | #Rotatable Bonds: 0 |
Polar Surface Area: 57.36 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.98 | CX Basic pKa: 5.23 | CX LogP: 2.16 | CX LogD: 2.15 |
Aromatic Rings: 5 | Heavy Atoms: 20 | QED Weighted: 0.44 | Np Likeness Score: 0.15 |
1. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R.. (2021) β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy., 64 (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887] |
Source(1):